SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-011379
Filing Date
2023-04-27
Accepted
2023-04-27 16:30:30
Documents
13
Period of Report
2023-04-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20230426_8k.htm   iXBRL 8-K 28161
  Complete submission text file 0001437749-23-011379.txt   180614

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rvph-20230425.xsd EX-101.SCH 4057
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20230425_def.xml EX-101.DEF 13923
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20230425_lab.xml EX-101.LAB 18268
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20230425_pre.xml EX-101.PRE 13945
7 EXTRACTED XBRL INSTANCE DOCUMENT rvph20230426_8k_htm.xml XML 4459
Mailing Address 19925 STEVENS CREEK BLVD. SUITE 100 CUPERTINO CA 95014
Business Address 19925 STEVENS CREEK BLVD. SUITE 100 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 23857569
SIC: 2834 Pharmaceutical Preparations